Using Bumetanide to Treat Autism in Children
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
PHASE3 · Tanta University · NCT04766177
This study is testing if Bumetanide can help reduce autism symptoms in children aged 3 to 12 years.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 3 Years to 12 Years |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta) |
| Trial ID | NCT04766177 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of Bumetanide, a diuretic, in treating children diagnosed with Autism Spectrum Disorder (ASD). It involves a Phase 3 interventional approach where participants aged 3 to 12 years will receive either Bumetanide or a placebo. The study aims to assess the impact of this medication on the symptoms of autism as measured by standardized scales. The trial will include children with a confirmed diagnosis of ASD while excluding those with certain neurological or medical conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 3 to 12 years diagnosed with Autism Spectrum Disorder.
Not a fit: Patients with autism associated with neurological conditions, hepatic or renal dysfunction, or specific syndromes will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for managing symptoms of autism in children.
How similar studies have performed: While the use of Bumetanide in autism is a novel approach, there have been limited studies exploring its effects, making this trial particularly significant.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients with ASD diagnosed by CARS rating Scale⩾30. 2. Age of patients range between (3-12) years. Exclusion Criteria: * Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Where this trial is running
Tanta
- Sherief Abd-Elsalam — Tanta, Egypt (RECRUITING)
Study contacts
- Principal investigator: Osama Elagamy, Prof — Pediatrics Department- Kafr-Elsheikh University
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Autism